ADAP Valuation

Adaptimmune Therapeutics PLC

Add to Watchlist

Advanced Chart

0.057

-0.002(-3.419%)1D

Overview
Forecast
Valuation
Earnings

ADAP Relative Valuation

ADAP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ADAP is overvalued; if below, it's undervalued.

Historical Valuation

Adaptimmune Therapeutics PLC (ADAP) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.28 is considered Undervalued compared with the five-year average of -3.61. The fair price of Adaptimmune Therapeutics PLC (ADAP) is between 0.25 to 0.89 according to relative valuation methord. Compared to the current price of 0.06 USD , Adaptimmune Therapeutics PLC is Undervalued By 77.47%.

Relative Value

Fair Zone

0.25-0.89

Current Price：0.06

77.47%

Undervalued

-0.24

Trailing

Forward

0.00

EV/EBITDA

Adaptimmune Therapeutics PLC. (ADAP) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.62. The thresholds are as follows: Strongly Undervalued below -14.85, Undervalued between -14.85 and -7.11, Fairly Valued between 8.36 and -7.11, Overvalued between 8.36 and 16.09, and Strongly Overvalued above 16.09. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.35

EV/EBIT

Adaptimmune Therapeutics PLC. (ADAP) has a current EV/EBIT of -0.35. The 5-year average EV/EBIT is -1.17. The thresholds are as follows: Strongly Undervalued below -4.18, Undervalued between -4.18 and -2.68, Fairly Valued between 0.34 and -2.68, Overvalued between 0.34 and 1.84, and Strongly Overvalued above 1.84. The current Forward EV/EBIT of -0.35 falls within the Historic Trend Line -Fairly Valued range.

0.28

Adaptimmune Therapeutics PLC. (ADAP) has a current PS of 0.28. The 5-year average PS is 47.32. The thresholds are as follows: Strongly Undervalued below -153.02, Undervalued between -153.02 and -52.85, Fairly Valued between 147.49 and -52.85, Overvalued between 147.49 and 247.66, and Strongly Overvalued above 247.66. The current Forward PS of 0.28 falls within the Historic Trend Line -Fairly Valued range.

-0.15

P/OCF

Adaptimmune Therapeutics PLC. (ADAP) has a current P/OCF of -0.15. The 5-year average P/OCF is -15.73. The thresholds are as follows: Strongly Undervalued below -131.32, Undervalued between -131.32 and -73.53, Fairly Valued between 42.06 and -73.53, Overvalued between 42.06 and 99.86, and Strongly Overvalued above 99.86. The current Forward P/OCF of -0.15 falls within the Historic Trend Line -Fairly Valued range.

-0.20

P/FCF

Adaptimmune Therapeutics PLC. (ADAP) has a current P/FCF of -0.20. The 5-year average P/FCF is -9.28. The thresholds are as follows: Strongly Undervalued below -70.00, Undervalued between -70.00 and -39.64, Fairly Valued between 21.08 and -39.64, Overvalued between 21.08 and 51.44, and Strongly Overvalued above 51.44. The current Forward P/FCF of -0.20 falls within the Historic Trend Line -Fairly Valued range.

Adaptimmune Therapeutics PLC (ADAP) has a current Price-to-Book (P/B) ratio of -0.22. Compared to its 3-year average P/B ratio of 3.17 , the current P/B ratio is approximately -106.90% higher. Relative to its 5-year average P/B ratio of 2.85, the current P/B ratio is about -107.66% higher. Adaptimmune Therapeutics PLC (ADAP) has a Forward Free Cash Flow (FCF) yield of approximately -1266.43%. Compared to its 3-year average FCF yield of -87.24%, the current FCF yield is approximately 1351.62% lower. Relative to its 5-year average FCF yield of -56.03% , the current FCF yield is about 2160.41% lower.

-0.22

P/B

Median3y

3.17

Median5y

2.85

-1266.43

FCF Yield

Median3y

-87.24

Median5y

-56.03

Competitors Valuation Multiple

The average P/S ratio for ADAP's competitors is 1.33, providing a benchmark for relative valuation. Adaptimmune Therapeutics PLC Corp (ADAP) exhibits a P/S ratio of 0.28, which is -78.95% above the industry average. Given its robust revenue growth of -89.33%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ADAP.O

Adaptimmune Therapeutics PLC

Calidi Biotherapeutics Inc

Loss

8.79M

Performance Decomposition

Market capitalization of ADAP decreased by 95.52% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.01 to -0.09.

The secondary factor is the Revenue Growth, contributed -89.33%to the performance.

Overall, the performance of ADAP in the past 1 year is driven by P/E Change. Which is more unsustainable.

-89.33%

128.23M → 13.68M

Revenue Growth

-509.13%

54.22 → -221.83

Margin Expansion

502.94%

-0.01 → -0.09

P/E Change

-95.52%